High dose celecoxib (C) and docetaxel (D) in patients (pts) with hormone resistant prostate cancer (HRPC). Results of an ongoing phase II trial.

被引：0
|
作者：
Kasimis, B
Cogswell, J
Hwang, S
Chang, VT
Srinivas, S
Zhong, F
Duque, L
Morales, E
Boholli, I
Blumenfrucht, M
机构：
[1] VA NJ Hlth Care Syst, E Orange, NJ USA
[2] VA New Jersey Hlth Care Syst, E Orange, NJ USA
[3] Univ Med & Dent New Jersey, VA New Jersey Hlth Care Syst, E Orange, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：428S / 428S
页数：1
相关论文
共 50 条
  • [1] Phase II trial of docetaxel (D) and high-dose celecoxib (C) in patients (Pts) with hormone resistant prostate cancer (HRPC).
    Kasimis, B
    Cogswell, J
    Hwang, S
    Chang, V
    Llorente, M
    Boholli, I
    Srinivas, S
    Morales, E
    Davis, C
    Blumenfrucht, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 410S - 410S
  • [2] Renal effects of high-dose celecoxib (CX) and docetaxel (D) During a phase II trial for hormone resistant prostate cancer (HRPC).
    Yudd, M
    Kasimis, B
    Chang, V
    Srinivas, S
    Hwang, S
    Sodagum, L
    Rana, I
    Anani, A
    Boholli, I
    Miller, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 444S - 444S
  • [3] Renal effects of high dose celecoxib (C) during 2 phase II trials for hormone resistant prostate cancer (HRPC).
    Yudd, M
    Kasimis, B
    Hwang, S
    Stanislaus, G
    McDowall, S
    Haastrup, A
    Penix, J
    Boholli, I
    Xia, Q
    Nazha, N
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 440S - 440S
  • [4] A phase II study of weekly docetaxel (T), estramustine (E), and celecoxib (C) in patients with hormone refractory prostate cancer (HRPC).
    Mellado, B
    Font, A
    Carles, J
    Catalán, G
    Larriba, JLG
    Gallardo, E
    Fernández, LA
    Nogué, M
    Lianes, P
    Del Alba, AG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 434S - 434S
  • [5] The addition of imatinib mesylate to estramustine/docetaxel (E/D) for the treatment of hormone refractory prostate cancer (HRPC) patients: Results of a phase I trial.
    Randall, M
    Rini, B
    Ryan, C
    Rosenberg, J
    Garcia, J
    Bubley, G
    Small, EJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 411S - 411S
  • [6] Phase II randomized trial of docetaxel plus estramustine (BE) versus docetaxel (D) in patients (pts) with hormone-refractory prostate cancer (HRPC): A final report.
    Eymard, JC
    Joly, F
    Priou, F
    Zannetti, A
    Ravaud, A
    Kerbrat, P
    Mousseau, M
    Paule, B
    Touze, F
    Ecstein-Fraisse, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 407S - 407S
  • [7] Results of a multicentric phase II randomized trial with docetaxel (D)±estramustine (E) as first line chemotherapy for patients (pts) with hormonerefractory advanced prostate cancer (HRPC)
    Caffo, O.
    Comploi, E.
    Sava, T.
    Mansueto, G.
    Zustovich, F.
    Segati, R.
    Sacco, C.
    Perin, A.
    Pappagallo, G.
    Valduga, F.
    Frisinghelli, M.
    Centonze, M.
    Galligioni, E.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 99 - 99
  • [8] Pilot phase II study with docetaxel in combination with curcuminoids in patients with hormone-resistant prostate cancer (HRPC).
    Mahammedi, H.
    Planchat, E.
    Cure, H.
    Barthomeuf, C.
    Bayet-Robert, M.
    Mouret-Reynier, M.
    Abrial, C.
    Thivat, E.
    Atger, M.
    Savareux, L.
    Guy, L.
    Goyard, J.
    Chollet, P. J. M.
    Nabholtz, J.
    Durando, X.
    Eymard, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Low dose docetaxel, estramustine and thalidomide followed by maintenance thalidomide for the treatment of hormone refractory prostate cancer (HRPC): A phase II community based trial.
    Frank, RC
    Coscia, A
    Versea, L
    Cohen, N
    Zelkowitz, R
    Ruskin, A
    Skeris, A
    Dodds, P
    Nair, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 426S - 426S
  • [10] Docetaxel (D) plus estramustine (E) versus D alone in patients (pts) with hormone-refractory prostate cancer (HRPC): Updated analysis of a phase II randomized trial
    Mousseau, Mireille
    Joly, Florence
    Priou, Franck
    Zannetti, Alain
    Ravaud, Alain
    Kerbrat, Pierre
    Paule, Bernard
    Touze, Florence
    Ecstein-Fraisse, Evelyne
    Eymard, Jean-Christophe
    ANNALS OF ONCOLOGY, 2004, 15 : 114 - 114
12345